Equities research analysts expect that Evolent Health Inc (NYSE:EVH) will report earnings of ($0.04) per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have made estimates for Evolent Health’s earnings, with estimates ranging from ($0.07) to ($0.03). Evolent Health posted earnings of ($0.18) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 77.8%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that Evolent Health will report full year earnings of ($0.36) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.33). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.06) per share, with EPS estimates ranging from ($0.13) to $0.03. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Evolent Health.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The firm had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. During the same period in the previous year, the company earned ($0.26) earnings per share. The company’s quarterly revenue was up 79.2% on a year-over-year basis.

Several equities analysts have commented on EVH shares. J P Morgan Chase & Co reiterated a “buy” rating on shares of Evolent Health in a report on Friday, August 18th. Leerink Swann set a $32.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a report on Friday, August 18th. Jefferies Group reiterated a “buy” rating and issued a $28.00 price objective on shares of Evolent Health in a report on Wednesday, September 6th. KeyCorp started coverage on shares of Evolent Health in a report on Tuesday, September 19th. They issued an “overweight” rating and a $23.00 price objective on the stock. Finally, SunTrust Banks reiterated a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company’s stock. Evolent Health has an average rating of “Buy” and an average target price of $28.00.

Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Evolent Health by 117.7% during the second quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock worth $250,073,000 after purchasing an additional 5,333,252 shares during the period. JPMorgan Chase & Co. lifted its position in Evolent Health by 37.3% during the third quarter. JPMorgan Chase & Co. now owns 7,465,019 shares of the technology company’s stock worth $136,236,000 after purchasing an additional 2,026,893 shares during the period. Vanguard Group Inc. lifted its position in Evolent Health by 48.9% during the second quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock worth $95,566,000 after purchasing an additional 1,237,941 shares during the period. Blair William & Co. IL lifted its position in Evolent Health by 31.4% during the second quarter. Blair William & Co. IL now owns 2,185,695 shares of the technology company’s stock worth $55,407,000 after purchasing an additional 522,874 shares during the period. Finally, TimesSquare Capital Management LLC lifted its position in Evolent Health by 5.7% during the third quarter. TimesSquare Capital Management LLC now owns 1,592,300 shares of the technology company’s stock worth $28,343,000 after purchasing an additional 86,300 shares during the period. Institutional investors and hedge funds own 95.38% of the company’s stock.

Evolent Health (NYSE:EVH) opened at $12.90 on Tuesday. Evolent Health has a fifty-two week low of $10.30 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34.

TRADEMARK VIOLATION NOTICE: “Evolent Health Inc (EVH) Expected to Post Earnings of -$0.04 Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/12/evolent-health-inc-evh-expected-to-post-earnings-of-0-04-per-share.html.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.